“Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata”, J of Skin, vol. 10, no. 2, p. s768, Mar. 2026, doi: 10.25251/bqftmw67.